These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 34090828)

  • 1. Diagnosis of malignant versus tuberculous ascites using tumor markers and globulin ratios in serum and ascites: A Fisher discriminant model.
    Yu T; Shu L; Chen Y; Zhu Y; Lu N; Lai Y; Huang T; Shu X
    Arab J Gastroenterol; 2021 Jun; 22(2):93-98. PubMed ID: 34090828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor markers in serum and ascites in the diagnosis of benign and malignant ascites.
    Zhu FL; Ling AS; Wei Q; Ma J; Lu G
    Asian Pac J Cancer Prev; 2015; 16(2):719-22. PubMed ID: 25684514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of biochemical parameters of ascitic fluid in exudative ascites with special reference to tuberculous peritonitis.
    Bandyopadhyay R; Bandyopadhyay SK; Ghosal J; Kumar U; Dutta A
    J Indian Med Assoc; 2006 Apr; 104(4):174, 176-7, 185. PubMed ID: 16910322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosing ascites: value of ascitic fluid total protein, albumin, cholesterol, their ratios, serum-ascites albumin and cholesterol gradient.
    Gupta R; Misra SP; Dwivedi M; Misra V; Kumar S; Gupta SC
    J Gastroenterol Hepatol; 1995; 10(3):295-9. PubMed ID: 7548806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic Accuracy of Tumor Markers CYFRA21-1 and CA125 in the Differential Diagnosis of Ascites.
    Trapé J; Gurt G; Franquesa J; Montesinos J; Arnau A; Sala M; Sant F; Casado E; Ordeig JM; Bergos C; Vida F; Sort P; Isava Á; González M; Molina R
    Anticancer Res; 2015 Oct; 35(10):5655-60. PubMed ID: 26408739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation.
    Kaleta EJ; Tolan NV; Ness KA; O'Kane D; Algeciras-Schimnich A
    Clin Biochem; 2013 Jun; 46(9):814-8. PubMed ID: 23454392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of serum and ascites fluid alpha-fetoprotein, carcinoembryonic antigen, CA 19-9, and CA 15-3 levels in differential diagnosis of ascites etiology.
    Sari R; Yildirim B; Sevinc A; Bahceci F; Hilmioglu F
    Hepatogastroenterology; 2001; 48(42):1616-21. PubMed ID: 11813585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ASCITIC AND SERUM LEVELS OF TUMOR BIOMARKERS (CA 72-4, CA 19-9, CEA AND CA 125) IN DISCRIMINATION OF CAUSE OF ASCITES: A PROSPECTIVE STUDY.
    Jain T; Ram S; Kumar H; Saroch A; Sharma V; Singh H
    Arq Gastroenterol; 2022; 59(2):198-203. PubMed ID: 35830029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of tumor markers for the differential diagnosis of benign and malignant ascites.
    Liu F; Kong X; Dou Q; Ye J; Xu D; Shang H; Xu K; Song Y
    Ann Hepatol; 2014; 13(3):357-63. PubMed ID: 24756011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis of malignancy-related ascites.
    Chen SJ; Wang SS; Lu CW; Chao Y; Lee FY; Lee SD; Wu SL; Cherng KL; Lo KJ
    J Gastroenterol Hepatol; 1994; 9(4):396-400. PubMed ID: 7948823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of tumour markers in ascitic fluid and serum: are measurements of ascitic tumour markers a futile attempt?
    Tuzun Y; Celik Y; Bayan K; Yilmaz S; Dursun M; Canoruc F
    J Int Med Res; 2009; 37(1):79-86. PubMed ID: 19215676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic algorithm based on ratio of ascites-serum tumor markers is superior to tumor markers in the differentiation of benign ascites from malignant ascites.
    Liu M; Zhang N; Wei X; Xiao Z; Song Y; Du L
    Am J Med Sci; 2024 Oct; 368(4):361-368. PubMed ID: 38880300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbohydrate antigen 125 and carcinoembryonic antigen in the differentiation of tuberculous peritonitis and peritonitis carcinomatosa.
    Tong H; Tai Y; Ye C; Wu H; Zhang LH; Gao JH; Yan ZP; Huang ZY; Tang CW
    Oncotarget; 2017 Sep; 8(44):78068-78075. PubMed ID: 29100448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to increase the diagnostic value of malignancy-related ascites: discriminative ability of the ascitic tumour markers.
    Tuzun Y; Yilmaz S; Dursun M; Canoruc F; Celik Y; Cil T; Boyraz T
    J Int Med Res; 2009; 37(1):87-95. PubMed ID: 19215677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of ascitic soluble human leukocyte antigen-G for distinguishing malignant ascites from benign ascites.
    Sun J; Chang YX; Niu CY
    Tumour Biol; 2017 Nov; 39(11):1010428317726840. PubMed ID: 29130388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of
    Han N; Sun X; Qin C; Hassan Bakari K; Wu Z; Zhang Y; Lan X
    AJR Am J Roentgenol; 2018 May; 210(5):1155-1163. PubMed ID: 29629798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a variety of biological parameters in distinguishing cirrhotic from malignant ascites.
    Alexandrakis MG; Moschandrea J; Kyriakou DS; Alexandraki R; Kouroumalis E
    Int J Biol Markers; 2001; 16(1):45-9. PubMed ID: 11288954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (1)H NMR spectroscopy of ascitic fluid: discrimination between malignant and benign ascites and comparison of the results with conventional methods.
    Bala L; Sharma A; Yellapa RK; Roy R; Choudhuri G; Khetrapal CL
    NMR Biomed; 2008 Jul; 21(6):606-14. PubMed ID: 18205245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ascitic fluid total protein, a useful marker in non-portal hypertensive ascites.
    Zhu S; Du L; Xu D; Lu Z; Xu T; Li J; Xu K; Ye J; Song Y
    J Gastroenterol Hepatol; 2020 Feb; 35(2):271-277. PubMed ID: 31247673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions.
    Trapé J; Molina R; Sant F
    Tumour Biol; 2004; 25(5-6):276-81. PubMed ID: 15627892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.